Meeting future vaccine and therapeutics demand with IVT-RNA manufacturing

RNA has attracted headlines in recent years for its use in Covid-19 vaccines, building on decades of research. And the use of RNA in drugs is only expected to increase in the years ahead to treat a range of conditions and offer protection via vaccines. Producing RNA synthetically through in-vitro transcription (IVT) offers a particular advantage in biopharma manufacturing. We assess the growing RNA market, the future threats, and the importance of quality control (QC) in delivering safe and effective products at the necessary pace and scale.